Retatrutide and gallbladder disease risk

Retatrutide is Eli Lilly's investigational peptide that activates three receptors at once: GLP-1, GIP and glucagon. It is not an approved medicine anywhere in our coverage area. The only lawful route to it is a clinical trial such as the Phase 3 TRIUMPH programme, whose lead obesity study finished its main analysis in April 2026^[4]. That has not stopped retatrutide from circulating outside trials, and a recurring question among people using it is what happens to the well-documented GLP-1 gallbladder signal in someone who no longer has a gallbladder. Here is what the trial and drug-label literature actually says, separate from any one person's situation.

The GLP-1 class has a real gallbladder signal

The connection between GLP-1 drugs and gallbladder disease is not speculation. A 2022 systematic review and meta-analysis in JAMA Internal Medicine pooled 76 randomized controlled trials and 103,371 participants and found that GLP-1 receptor agonist treatment increased the risk of gallbladder or biliary disease by 37 percent, risk ratio 1.37, 95 percent CI 1.23 to 1.52^[1]. Broken down further, cholelithiasis (gallstones) rose 27 percent and cholecystitis (gallbladder inflammation) rose 36 percent. The increase was concentrated in trials that used a GLP-1 drug for weight loss rather than diabetes, and in trials that ran longer than 26 weeks^[1].

The mechanism is reasonably well characterized. GLP-1 receptor agonists suppress the release of cholecystokinin, the hormone that signals the gallbladder to contract after a meal^[5]. Less contraction means bile sits in the gallbladder longer between meals, and rapid weight loss independently raises the cholesterol content of that bile. Cholesterol-saturated, slow-moving bile is the standard recipe for gallstone formation.

That mechanism shows up in an approved product's own label. Novo Nordisk's Wegovy (semaglutide) prescribing information states that treatment is associated with an increased occurrence of cholelithiasis and cholecystitis, and lists cholelithiasis in 1.6 percent of adults on the injection versus 0.7 percent on placebo, and cholecystitis in 0.6 percent versus 0.2 percent, in the trials that supported approval^[2].

What retatrutide's own trials show

Retatrutide is not semaglutide, and it is not tirzepatide, the dual GLP-1 and GIP agonist marketed as Mounjaro and Zepbound. But retatrutide activates the same GLP-1 receptor that drives the class-wide gallbladder signal, plus the GIP and glucagon receptors on top, so the mechanism plausibly still applies. The Phase 2 obesity trial reported that adverse events in the retatrutide groups were dominated by gastrointestinal symptoms, nausea, vomiting, diarrhea and constipation, without breaking out a separate gallbladder or biliary disease category in the published summary^[3]. That silence is not the same as zero events. A trial of 338 participants may simply not generate enough gallbladder-specific events to report as their own line item.

The Phase 3 TRIUMPH programme is the dataset that could resolve this at scale. TRIUMPH-1 enrolled 2,335 participants and completed its primary analysis in April 2026^[4], but the full peer-reviewed safety paper had not published a gallbladder-specific breakdown as of this writing. Until that paper, or a pooled TRIUMPH safety analysis, appears, the honest position is that retatrutide's own gallbladder risk, as distinct from the wider GLP-1 class risk, is not yet quantified in the public record.

Without a gallbladder, the physiology changes

Cholelithiasis and cholecystitis are, by definition, diseases of the gallbladder. Remove the organ surgically and those two specific diagnoses are no longer possible. But a cholecystectomy does not remove the rest of the biliary tree, and people who no longer have a gallbladder are not risk-free. Post-cholecystectomy syndrome, a cluster of symptoms that can include right-upper-quadrant pain, bile acid diarrhea, and retained or recurrent stones in the common bile duct, affects an estimated 5 to 47 percent of people after the surgery^[6].

Bile acid diarrhea happens because bile can no longer be stored between meals. Instead it drips continuously into the small intestine, and when more bile acid reaches the colon than the gut can reabsorb, it draws in water and speeds transit^[6]. Here is the article's most important gap: no trial cited in this piece enrolled participants because they lacked a gallbladder, and none of the published papers report a post-cholecystectomy subgroup. If a triple agonist slows gut and biliary motility the way the mechanism literature describes, the more plausible concern in someone without a gallbladder is an exacerbation of existing bile acid diarrhea, or a retained common bile duct stone becoming symptomatic, rather than a new gallstone. That is a reasoned inference from the physiology, not a finding from a dedicated trial, and it should be treated as such.

What this is not, and what to do with it

This is not a personalized answer to any one reader's weight-loss plateau, and it is not a verdict on whether a missing gallbladder explains it. Rapid weight loss, independent of any specific drug, is a well-established contributor to gallstone risk, which is consistent with the meta-analysis above finding a larger risk increase in weight-loss trials than in diabetes trials using the same drugs^[1]. That makes it hard to separate a drug effect from a weight-loss effect in any single case. Self-directed dosing decisions based on a forum thread are not a substitute for a clinician who can examine someone directly.

Retatrutide remains investigational. It is being evaluated in trials such as TRIUMPH-1^[4], not sold as an approved medicine, and vials obtained outside a trial sit outside the manufacturing and quality controls that produced the label data behind Wegovy's numbers^[2]. If you are considering a GLP-1, GIP or glucagon-based peptide and you do not have a gallbladder, the useful step is the unglamorous one: tell your prescriber about the surgery, mention any post-surgical bile symptoms, and ask them to watch for right-upper-quadrant pain, fever or jaundice during dose escalation, the same warning signs that matter for anyone on this drug class.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. It does not address any individual's dosing, symptoms or research use. Always consult a qualified healthcare professional before starting, stopping or continuing any peptide, and before interpreting gastrointestinal symptoms as gallbladder-related. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.